ClinicalTrials.gg
CompletedNCT06212960Updated Apr 4, 2024

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

A Phase 1 interventional study of DWP712 and BOTOX® in Glabellar Lines, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

02

Conditions studied

  • Glabellar Lines
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    DWP712

    Patients were intramuscularly injected (IM) with a total of 20U of DWP712 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.

    Biological: DWP712

  • Active comparator
    Botox®

    Patients were intramuscularly injected (IM) with a total of 20U of BOTOX® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.

    Biological: BOTOX®

Interventions

  • BiologicalDWP712

    Clostridium botulinum Toxin

  • BiologicalBOTOX®

    Clostridium botulinum Toxin

06

What researchers measure

Primary outcomes

  1. Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0

    Time frame: At 4, 8, 12 week after the injection

07

Study locations

1 site
  • Chung-Ang University Hosptial
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 19, 2024
StartActual
Nov 28, 2023
Primary completionActual
Feb 26, 2024
CompletionActual
Mar 21, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06212960
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Nov 28, 2023
Primary completion
Feb 26, 2024
Completion
Mar 21, 2024
Last update
Apr 4, 2024

Study contacts

Beom Joon Kim, MD, Ph.D
principal investigator · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion